{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:15:20Z","timestamp":1787652920264,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-025-00752-3","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T02:08:41Z","timestamp":1752286121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms"],"prefix":"10.1007","volume":"20","author":[{"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela S.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsewang","family":"Tashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennex Hsueh-Lin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"4","key":"752_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced international prognostic score system for Transplantation-Age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310\u20138.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"752_CR2","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/blood-2023-182624","volume":"142","author":"H Chang","year":"2023","unstructured":"Chang H, Kao HW, Kuo MC, et al. Genetic evolution from chronic myeloproliferative neoplasms to acute myeloid leukemia: an analysis of forty-six paired samples. Blood. 2023;142(Supplement 1):3155.","journal-title":"Blood"},{"issue":"19","key":"752_CR3","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Rampal R, Manshouri T, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood. 2012;119(19):4480\u20135.","journal-title":"Blood"},{"issue":"7","key":"752_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1055\/a-2239-9265","volume":"124","author":"A Segura-D\u00edaz","year":"2024","unstructured":"Segura-D\u00edaz A, Stuckey R, Florido Y, et al. DNMT3A\/TET2\/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study. Thromb Haemost. 2024;124(7):669\u201375.","journal-title":"Thromb Haemost"},{"issue":"1","key":"752_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41408-023-00947-y","volume":"13","author":"Y Yang","year":"2023","unstructured":"Yang Y, Abbas S, Sayem MA, Dutta A, Mohi G. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm. Blood Cancer J. 2023;13(1):171.","journal-title":"Blood Cancer J"},{"key":"752_CR6","unstructured":"Gagelmann N, Badbaran A, Salit RB et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation [published correction appears in Blood. 2024;143(18):1879]. Blood. 2023;141(23):2901-11."},{"issue":"6","key":"752_CR7","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790\u20137.","journal-title":"Blood"},{"issue":"6","key":"752_CR8","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00277-024-05754-4","volume":"103","author":"CC Chen","year":"2024","unstructured":"Chen CC, Chen JL, Lin AJ, Yu LH, Hou HA. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis. Ann Hematol. 2024;103(6):1947\u201365.","journal-title":"Ann Hematol"},{"issue":"11","key":"752_CR9","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1182\/bloodadvances.2021005344","volume":"6","author":"G Tan","year":"2022","unstructured":"Tan G, Wolski WE, Kummer S, et al. Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells. Blood Adv. 2022;6(11):3480\u201393.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"752_CR10","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1182\/blood-2023-182703","volume":"142","author":"S Hu","year":"2023","unstructured":"Hu S, Yang X, Zhu J, Huang J. Clinical and genetic features by next-generation sequencing and RNA sequencing in pre-fibrotic primary myelofibrosis patients. Blood. 2023;142(Supplement 1):1836.","journal-title":"Blood"},{"key":"752_CR11","doi-asserted-by":"publisher","first-page":"665037","DOI":"10.3389\/fonc.2021.665037","volume":"11","author":"JG Cominal","year":"2021","unstructured":"Cominal JG, Cacemiro MDC, Berzoti-Coelho MG, et al. Bone marrow soluble mediator signatures of patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Front Oncol. 2021;11:665037.","journal-title":"Front Oncol"},{"issue":"7","key":"752_CR12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ajh.27322","volume":"99","author":"EJ Cuenca-Zamora","year":"2024","unstructured":"Cuenca-Zamora EJ, Guijarro-Carrillo PJ, L\u00f3pez-Poveda MJ, et al. miR-146a\u2013\/\u2013 mice model reveals that NF-\u03baB Inhibition reverts inflammation-driven myelofibrosis-like phenotype. Am J Hematol. 2024;99(7):1326\u201337.","journal-title":"Am J Hematol"},{"issue":"23","key":"752_CR13","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood.2024024451","volume":"143","author":"JY Sullivan","year":"2024","unstructured":"Sullivan JY, Fleischman AG. Relating NF-\u03baB regulation to MPN pathogenesis. Blood. 2024;143(23):2345\u201347.","journal-title":"Blood"},{"issue":"5","key":"752_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.2019001113","volume":"134","author":"S Cordua","year":"2019","unstructured":"Cordua S, Kjaer L, Skov V, Pallisgaard N, Hasselbalch HC, Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469\u201379.","journal-title":"Blood"},{"issue":"19","key":"752_CR15","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1182\/bloodadvances.2023010588","volume":"7","author":"MH Kristiansen","year":"2023","unstructured":"15, Kristiansen MH, Kj\u00e6r L, Skov V, et al. JAK2V617F mutation is highly prevalent in patients with ischemic stroke: a case-control study. Blood Adv. 2023;7(19):5825\u201334.","journal-title":"Blood Adv"},{"issue":"15","key":"752_CR16","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139.","journal-title":"Blood"},{"issue":"3","key":"752_CR17","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study [published correction appears in lancet haematol. 2020;7(4):e279]. Lancet Haematol. 2020;7(3):e196\u2013208.","journal-title":"Lancet Haematol"},{"issue":"10","key":"752_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/s41375-023-02008-6","volume":"37","author":"H Gisslinger","year":"2023","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment. Leukemia. 2023;37(10):2129\u201332.","journal-title":"Leukemia"},{"issue":"5","key":"752_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","volume":"36","author":"JJ Kiladjian","year":"2022","unstructured":"Kiladjian JJ, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408\u201311.","journal-title":"Leukemia"},{"key":"752_CR20","doi-asserted-by":"crossref","unstructured":"Barbui T, Vannucchi AM, De Stefano V et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial [published correction appears in Lancet Haematol. 2021;8(3):e170]. Lancet Haematol. 2021;8(3):e175-e184.","DOI":"10.1016\/S2352-3026(20)30373-2"},{"issue":"2","key":"752_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00277-023-05577-9","volume":"103","author":"T Barbui","year":"2024","unstructured":"Barbui T, Carobbio A, De Stefano V, et al. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. Ann Hematol. 2024;103(2):437\u201342.","journal-title":"Ann Hematol"},{"issue":"1","key":"752_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40164-023-00415-0","volume":"12","author":"J Jin","year":"2023","unstructured":"Jin J, Zhang L, Qin A, et al. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol. 2023;12(1):55.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"752_CR23","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/bjh.19846","volume":"205","author":"S Suo","year":"2024","unstructured":"Suo S, Fu RF, Qin A, et al. Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. Br J Haematol. 2024;205(6):2510\u20134.","journal-title":"Br J Haematol"},{"issue":"1\u20132","key":"752_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14740\/jh1245","volume":"13","author":"SS Suo","year":"2024","unstructured":"Suo SS, Fu RF, Qin A, et al. Effective management of polycythemia vera with ropeginterferon alfa-2b. J Hematol. 2024;13(1\u20132):12\u201322.","journal-title":"J Hematol"},{"key":"752_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35411","author":"SY Yoon","year":"2025","unstructured":"Yoon SY, Yoon SS, Yang DH, et al. Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study. Int J Cancer. 2025. https:\/\/doi.org\/10.1002\/ijc.35411.","journal-title":"Int J Cancer"},{"issue":"1","key":"752_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s44313-024-00026-6","volume":"59","author":"SY Yoon","year":"2024","unstructured":"Yoon SY, Lee SE. Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South korea: one-year results from a phase 2 study. Blood Res. 2024;59(1):23.","journal-title":"Blood Res"},{"issue":"2","key":"752_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study [published correction appears in int J hematol. 2022;116(4):642\u2013643]. Int J Hematol. 2022;116(2):215\u201327.","journal-title":"Int J Hematol"},{"issue":"6","key":"752_CR28","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s12185-024-03846-5","volume":"120","author":"K Kirito","year":"2024","unstructured":"Kirito K, Sugimoto Y, Gotoh A, et al. Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol. 2024;120(6):675\u201383.","journal-title":"Int J Hematol"},{"issue":"Suppl 1","key":"752_CR29","doi-asserted-by":"publisher","first-page":"6397","DOI":"10.1182\/blood-2023-191268","volume":"142","author":"T Tashi","year":"2023","unstructured":"Tashi T, Reeves BN, Kim SJ, et al. Real-world experience of ropeginterferon-alfa treatment of PV and ET: two centers experience. Blood. 2023;142(Suppl 1):6397.","journal-title":"Blood"},{"issue":"2","key":"752_CR30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","volume":"120","author":"CE Huang","year":"2021","unstructured":"Huang CE, Wu YY, Hsu CC, et al. Real-world experience with ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms. J Formos Med Assoc. 2021;120(2):863\u201373.","journal-title":"J Formos Med Assoc"},{"key":"752_CR31","doi-asserted-by":"publisher","first-page":"1109866","DOI":"10.3389\/fonc.2023.1109866","volume":"13","author":"A Qin","year":"2023","unstructured":"Qin A, Urbanski RW, Yu L, Ahmed T, Mascarenhas J. An alternative dosing strategy for ropeginterferon alfa-2b May help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future. Front Oncol. 2023;13:1109866.","journal-title":"Front Oncol"},{"issue":"3","key":"752_CR32","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1111\/bjh.19998","volume":"206","author":"A Qin","year":"2025","unstructured":"Qin A, Zhang L, Jin J. The higher initial dose and accelerated Titration regimen of ropeginterferon as a treatment option for certain patients with polycythaemia vera. Br J Haematol. 2025;206(3):986\u20137.","journal-title":"Br J Haematol"},{"key":"752_CR33","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/bcp.16043","volume":"90","author":"A Qin","year":"2024","unstructured":"Qin A, Wu D, Li Y, et al. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera. Br J Clin Pharmacol. 2024;90:1493\u2013502.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"752_CR34","doi-asserted-by":"publisher","first-page":"e30559","DOI":"10.1002\/pbc.30559","volume":"70","author":"N Kucine","year":"2023","unstructured":"Kucine N, Jessup JA, Cooper TM, et al. Position paper: the time for cooperative group study of ropeginterferon alfa-2b in young patients with myeloproliferative neoplasms is now. Pediatr Blood Cancer. 2023;70(10):e30559.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"752_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-025-02545-2","volume":"39","author":"Y Beauverd","year":"2025","unstructured":"Beauverd Y, Ianotto JC, Thaw KH, et al. Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. Leukemia. 2025;39(5):1135\u201345.","journal-title":"Leukemia"},{"issue":"19","key":"752_CR36","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1182\/blood.2021012743","volume":"139","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931\u201341.","journal-title":"Blood"},{"issue":"27","key":"752_CR37","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2217\/fon-2022-0596","volume":"18","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Komatsu N, Gill H, et al. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus Anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022;18(27):2999\u20133009.","journal-title":"Future Oncol"},{"issue":"18","key":"752_CR38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood.2019000428","volume":"134","author":"A Yacoub","year":"2019","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498\u2013509.","journal-title":"Blood"},{"issue":"1","key":"752_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","volume":"41","author":"HC Hasselbalch","year":"2019","unstructured":"Hasselbalch HC, Holmstr\u00f6m MO. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Semin Immunopathol. 2019;41(1):5\u201319.","journal-title":"Semin Immunopathol"},{"issue":"12","key":"752_CR40","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1097\/HS9.0000000000000645","volume":"5","author":"HC Hasselbalch","year":"2021","unstructured":"Hasselbalch HC, Silver RT. New perspectives of interferon-alpha2 and inflammation in treating Philadelphia-negative chronic myeloproliferative neoplasms. Hemasphere. 2021;5(12):e645.","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"752_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-141223","volume":"136","author":"RD De Oliveira","year":"2020","unstructured":"De Oliveira RD, Soret-Dulphy J, Zhao LP, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Suppl 1):35\u20136.","journal-title":"Blood"},{"issue":"19","key":"752_CR42","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534\u201344.","journal-title":"J Clin Oncol"},{"issue":"9","key":"752_CR43","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1007\/s00277-024-05912-8","volume":"103","author":"G Abu-Zeinah","year":"2024","unstructured":"Abu-Zeinah G, Qin A, Gill H, et al. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early\/lower-risk primary myelofibrosis. Ann Hematol. 2024;103(9):3573\u201383.","journal-title":"Ann Hematol"},{"issue":"Suppl 1","key":"752_CR44","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2022-169613","volume":"140","author":"H Gill","year":"2022","unstructured":"Gill H, Au L, Yim R, et al. Efficacy and safety of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low\/intermediate-1 risk myelofibrosis. Blood. 2022;140(Suppl 1):1522.","journal-title":"Blood"},{"issue":"11","key":"752_CR45","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/cncr.34707","volume":"129","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Kiladjian JJ, Vannucchi AM, et al. Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies. Cancer. 2023;129(11):1681\u201390.","journal-title":"Cancer"},{"issue":"5","key":"752_CR46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189(5):888\u2013903.","journal-title":"Br J Haematol"},{"key":"752_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03572-3","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03572-3.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"752_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood-2023-181971","volume":"142","author":"H Gill","year":"2023","unstructured":"Gill H, Au L, Leung GMK, et al. Phase 2 study to assess the safety and efficacy of Bomedemstat (MK3543) in combination with ruxolitinib in patients with myelofibrosis. Blood. 2023;142(Suppl 1):621.","journal-title":"Blood"},{"issue":"7","key":"752_CR49","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","volume":"25","author":"D Yan","year":"2019","unstructured":"Yan D, Pomicter AD, Tantravahi S, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25(7):2323\u201335.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"752_CR50","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/14796694.2025.2461393","volume":"21","author":"J Mascarenhas","year":"2025","unstructured":"Mascarenhas J, Maher K, Rampal R, et al. Selinexor plus ruxolitinib in JAK inhibitor treatment-na\u00efve myelofibrosis: SENTRY phase 3 study design. Future Oncol. 2025;21(7):807\u201313.","journal-title":"Future Oncol"},{"issue":"20","key":"752_CR51","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1182\/bloodadvances.2024013170","volume":"8","author":"AL S\u00f8rensen","year":"2024","unstructured":"S\u00f8rensen AL, Skov V, Kj\u00e6r L, et al. Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. Blood Adv. 2024;8(20):5416\u201325.","journal-title":"Blood Adv"},{"issue":"Suppl","key":"752_CR52","doi-asserted-by":"publisher","first-page":"e83600cf","DOI":"10.1097\/01.HS9.0000975592.83600.cf","volume":"7","author":"S Wang","year":"2023","unstructured":"Wang S, Zhang L, Jin K, et al. PB2211: differences in post-polycythemia vera and post-essential thrombocythemia myelofibrosis vs. primary myelofibrosis in fibrotic stage: a retrospective, real-world study conducted in China. Hemasphere. 2023;7(Suppl):e83600cf.","journal-title":"Hemasphere"},{"issue":"10","key":"752_CR53","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3346\/jkms.2016.31.10.1579","volume":"31","author":"Y Lim","year":"2016","unstructured":"Lim Y, Lee JO, Bang SM. Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea. J Korean Med Sci. 2016;31(10):1579\u201385.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"752_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00277-016-2902-9","volume":"96","author":"JM Byun","year":"2017","unstructured":"Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population-based study in Korea 2004\u20132013. Ann Hematol. 2017;96(3):373\u201381.","journal-title":"Ann Hematol"},{"key":"752_CR55","doi-asserted-by":"publisher","first-page":"204062072311793","DOI":"10.1177\/20406207231179331","volume":"14","author":"TH Tsai","year":"2023","unstructured":"Tsai TH, Yu LH, Yu MS, et al. Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study. Ther Adv Hematol. 2023;14:20406207231179331.","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"752_CR56","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70\u2009+\u2009Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769\u201370.","journal-title":"J Clin Oncol"},{"issue":"12","key":"752_CR57","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726\u201331.","journal-title":"Leukemia"},{"key":"752_CR58","first-page":"118","volume":"193","author":"IWC Sanchez","year":"2021","unstructured":"Sanchez IWC, Durgam G, Curto-Garcia N, Sullivan JO, Robinson SE, Ali S, McLornan D, Harrison C. A case of polycythaemia vera treated with ropeginterferon-2b during pregnancy. Br J Haematol. 2021;193:118\u20139.","journal-title":"Br J Haematol"},{"issue":"1","key":"752_CR59","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/hematolrep15010018","volume":"15","author":"SY Bang","year":"2023","unstructured":"Bang SY, Lee SE. A case report of ropeginterferon alfa-2b for polycythemia vera during pregnancy. Hematol Rep. 2023;15(1):172\u20139.","journal-title":"Hematol Rep"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-025-00752-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-025-00752-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:03:44Z","timestamp":1769051024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-025-00752-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s11899-025-00752-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"10 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prithviraj Bose: Grants (Incyte, CTI, MorphoSys, Kartos, Telios, Ionis, Disc, Blueprint, Cogent, Geron, Janssen, Sumitomo, BMS, Karyopharm); consulting fees (Incyte, BMS, CTI, GSK, AbbVie, MorphoSys, Karyopharm, PharmaEssentia, Blueprint, Cogent, Novartis, Jubilant, Morphic, Ono, Sumitomo); honoraria for lectures\/advisory boards (Incyte, Blueprint, GSK, CTI, AbbVie, Sumitomo, PharmaEssentia). Zhijian Xiao: no competing interests to declare. Hans C. Hasselbalch: Data Monitoring Board honoraria from AOP Health and grants from Novartis. Josef T. Prchal: AbbVie: Research Funding; PharmaEssentia: Research Funding. Minghui Duan: no competing interests to declare. Abdulraheem Yacoub: Consulting fees (Incyte, CTI Pharma, PharmaEssentia, Pfizer, Novartis, Acceleron Pharma, Servier, AbbVie, Apellis, Gilead, Notable Labs); meeting\/travel support (Incyte). Raajit K. Rampal: Grants (Incyte, Ryvu, MorphoSys, Zentalis); consulting fees (MorphoSys, CTI, GSK, Stemline, Blueprint, SDP, Servier, Zentalis, BMS, Galectco, AbbVie, PharmaEssentia, Cogent, Kartos); honoraria for lectures\/advisory boards (Protagonist, Karyopharm, GSK); monitoring or advisory board (Kartos). Jean-Jacques Kiladjian; grants and personal fees from AOP Health, and personal fees from Novartis, BMS\/Celgene, AbbVie, and PharmaEssentia. Gabriela Hobbs: Grants (Incyte); consulting fees (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys, Cogent, Pharmaxis); monitoring or advisory board (PharmaEssentia, Protagonist, AbbVie, GSK, Pfizer, Novartis, MorphoSys); stock\/stock options (Regeneron Pharmaceuticals). Tsewang Tashi: Blueprint (consultancy, research funding), PharmaEssentia (consultancy, research funding), Cogent (consultancy, research funding), CITI Biopharma (consultancy), Italfarmaco (research funding), and Telios (research funding) Kazuya Shimoda: a consultant for Sierra Oncology, Inc. and reports research funding from AbbVie G.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., PharmaEssentia Japan K.K., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. and honoraria from Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and is a member of an advisory committee for AbbVie G.K. Keita Kirito: received honoraria for lectures, presentations, speaking engagements, manuscript writing, and educational events from AbbVie G.K., Novartis Pharma K.K., PharmaEssentia Japan K.K., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. Harinder Gill: Consulting fees\/Speaker fees from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Advisory board for Abbvie, Bristol Myers Squibb, GSK, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Celgene, MSD, Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer. Hsin-An Hou: Consulting fees\/Speaker fees\/ honoraria from Abbvie, Bristol Myers Squibb, GSK, MSD, Novartis, PharmaEssentia Corporation and Pfizer, Research support from Novartis and PharmaEssentia Corporation, Conference support from Bristol Myers Squibb, MSD, Novartis, Otsuka, PharmaEssentia and Pfizer. Sung-Eun Lee: no competing interests to declare. Jian Huang: no competing interests to declare. Bing Li: no competing interests to declare. Albert Qin: serving as the chief medical officer of PharmaEssentia Corporation. Lennex Hsueh-Lin Yu: employed at PharmaEssentia. John Mascarenhas: Grants (PharmaEssentia, Novartis, Roche, Geron, Abbie, Kartos, Karyopharm); consulting fees (PharmaEssentia, CTI, Incyte, Roche, Novartis, Merck, Geron, AbbVie, BMS, Kartos, MorphoSys, Galecto, Imago); honoraria for lectures\/advisory boards (BMS); monitoring or advisory board (Incyte, Galecto); meeting\/travel support (Kartos). Ruben A. Mesa: Consulting fees (Incyte, PharmaEssentia, CTI, AbbVie, GSK, BMS, Genentech).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"9"}}